Introduction
Clinical pharmacology and toxicokinetics
Drug | MW (Da) | Protein binding (%) | VD (L/kg) | F (%) | TMAX (h) | Endogenous T1/2 (h) | Endogenous CL (mL/min) | Renal CL (mL/min), Normal GFR | Therapeutic range (mg/L) | References | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Normal GFR | CKD | Normal GFR | ESKD | Normal GFR | ESKD | ||||||||
Acebutolol | 336 | 10–25 | 1.5–2.5 | N/A | 35–50 | 2.0–4.0 | 4–10& | 600–800 | N/A | 150–300 | 0.2–2 | ||
Alprenolol | 249 | 80–90 | 2.5–3.5 | N/A | 5–15 | 1.0–2.0 | 2–4 | N/A | 800–1000 | N/A | 50 | 0.03–0.15 | |
Atenolol | 266 | 0–5 | 1.0–1.2 | 50–60 | 3.0–3.5 | 5–8 | 50–100 | 140–180 | 20 | 120–140 | 0.1–1.5 | ||
Betaxolol | 344 | 50 | 4.5–6.0 | 5.0–6.5 | 75–90 | 2.5–4.0 | 14–16 | 25–35 | 220–270 | 100–150 | 50 | 0.005–0.05 | |
Bisoprolol | 325 | 30 | 2.0–3.0 | 90 | 1.5–2.5 | 9–12 | 25–35 | 200–250 | 50 | 120–150 | 0.01–0.1 | ||
Bopindolol | 381 | N/A | 1.8–2.0 | N/A | 70 | 1.0–2.0 | 4–6 | 8 | 350–400 | N/A | N/A | 0.001–0.015 | |
Carteolol | 292 | 10–30 | 4 | N/A | 85 | 2.0 | 5–7 | 30–35 | 650 | N/A | 250 | 0.01–0.1 | |
Carvedilol | 405 | 98 | 1.5–2.5 | N/A | 20–30 | 1.0–3.0 | 6–7 | 600 | 5 | 0.02–0.2 | |||
Celiprolol | 379 | 25 | 4–5 | N/A | 30–70 | 2.0–4.0 | 5–7 | N/A | 900–1000 | N/A | 180–220 | 0.05–0.5 | |
Cetamolol | 310 | N/A | 3.5 | 2.5 | N/A | 2.5–3.0 | 7 | 10–12 | 420* | 150 | 100–150 | 0.01–0.1 | |
Esmolol | 295 | 55 | 2.0–3.5 | Not applicable | 0.2 | 10,000–15,000 | 100–200 | 0.15–2 | |||||
Labetalol | 328 | 50 | 5.0–9.0 | 20–30 | 0.5–1.5 | 3–10 | 10–12 | 1200–2000 | 20 | 0.03–0.3 | |||
Medroxalol | 372 | N/A | 10–15 | N/A | 30–50 | 2–3 | 7–15 | N/A | 1000–1100 | N/A | 80–100 | N/A | |
Mepindolol | 262 | 55 | 5.7** | N/A | N/A | 1.4 | 3–6 | 650** | N/A | 0** | 0.007–0.07 | ||
Metipranolol | 309 | 70 | 3–4 | N/A | 40–50 | 0.5–2.0 | 2.5–3.0 | 1100–1300 | N/A | 120–150 | 0.02–0.1 | ||
Metoprolol | 267 | 10 | 3.0–4.0 | N/A | 40–60 | 1.5–2.0 | 3–5 | 800–1200 | 100 | 0.03–0.5 | |||
Nadolol | 309 | 15–25 | 1.5–2.0 | N/A | 30 | 2.8 | 10–15 | 30–45 | 120–250 | 30 | 80–120 | 0.01–0.25 | |
Nebivolol | 405 | 98 | 9–12 | Variable | 1–3 | 10–15 | 800–1000 | 30 | 0.001–0.05 | ||||
Oxprenolol | 265 | 80–85 | 0.8–1.2 | 0.8 | 35–50 | 0.5–1.5 | 1–2 | 600–750 | 550 | 10 | 0.05–0.3 | ||
Penbutolol | 291 | 90–95 | 0.5–1.0 | N/A | 90 | 1.0–2.0 | 15–20 | 30 | 300–600 | N/A | 5 | 0.01–0.3 | |
Pindolol | 248 | 40–55 | 1.3–2.3 | 1.6–1.8 | 50–90 | 0.5–1.5 | 3–5 | 450–550 | 180–240 | 150–250 | 0.02–0.15 | ||
Practolol | 266 | 57 | 1.5 | N/A | 90–100 | 2–5 | 10–13 | 60–80 | 135 | 20 | 100–120 | 1.5–5 | |
Prenalterol | 225 | 5 | 2.5–3.5 | N/A | 25–35 | 0.5–2.5 | 1.5–2.5 | N/A | 800–1400 | N/A | 200–800 | 0.01–0.04 | |
Propranolol | 259 | 85–95 | 3.0–5.0 | 20–50 | 1.5–2.0 | 3–5 | 800–1200 | 5 | 0.02–0.3 | ||||
Sotalol | 272 | 0 | 1.3–1.5 | 90 | 2.5–3.5 | 5–9 | 35–60 | 120–160 | 20–25 | 80–120 | 0.5–3 | ||
Talinolol | 363 | 60** | 3.0–3.5 | 55 | 2.5–3.5 | 10–12 | 20–25 | 320–380 | 150–200 | 0.04–0.15 | |||
Timolol | 316 | 10 | 2.0–2.5 | N/A | 60 | 1.3–2.0 | 3–5 | 450–580 | N/A | 100 | 0.005–0.1 | ||
Tolamolol | 316 | 90 | 1.2–1.8 | N/A | N/A | 1–3 | 2–3 | 1100 | N/A | N/A | N/A |
Overview of toxicity
Methods
Results
Summary of evidence
Dialyzability
Drug | ECTR | T1/2 (Hours) | Clearance (mL/min) | References | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
During ECTR | Endogenous | ECTR | Endogenous | |||||||||
Median | n | Range | Normal GFR | ESKD | Median | n | Range | Normal GFR | ESKD | |||
Acebutolol | HD | 6.1 (Met = 7.2) | 7 | 2.2–7 | 4–10 | 45 (Met = 33.6) | 12 | 30.5–55.1 | 600–800 | N/A | ||
HF-HP | 0.3 | 1 | 151 | 1 | ||||||||
Atenolol | HD | 4.6 | 48 | 0.5–17.8 | 5–8 | 50–100 | 119.5 | 25 | 18–311 | 140–180 | 20 | |
CKRT | 22 | 2 | 14.5–29.5 | 47 | 3 | 19.9–48 | ||||||
HD-HP | 3.4 | 1 | N/A | |||||||||
PD | 23 | 17 | 19.2–34 | 2.6 | 7 | 1.3–3.7 | ||||||
Betaxolol | HD | N/A | 14–16 | 25–35 | 17.5 ± 0.7 | 12 | 220–270 | 100–150 | [86] | |||
PD | N/A | 11.7 ± 1.2 | 12 | |||||||||
Bisoprolol | HD | 7.8 | 16 | 6.4–9.6 | 9–12 | 25–35 | 41.8 | 16 | 30.5–70 | 200–250 | 50 | |
PD | 23.6 | 3 | 20.8–26.4 | N/A | ||||||||
Carvedilol | HD | 4.6 | 8 | 4.1–5.3 | 6–7 | 12.1 | 14 | 12.1–38.6 | 600 | |||
Esmolol | HD | 0.12 ± 0.1 | 6 | 0.2 | Met = 76.8 ± 39.1 | 6 | 10,000–15,000 | [95] | ||||
PD | 0.13 ± 0.1 | 6 | Met = 2.7 ± 0.5 | 6 | ||||||||
Labetalol | HD | 1.8 | 7 | 0.6–3.8 | 3–10 | 10–12 | 37.4 | 14 | 25.7–97 | 1200–2000 | ||
PD | 13.1 ± 6.3 | 8 | 1.9 ± 1.7 | 8 | ||||||||
Mepindolol | HD | 3.0 | 2 | 3–6 | 31 | 2 | 650 | N/A | [88] | |||
Metipranolol | HD | 1.4 ± 0.5 | 8 | 2.5–3.0 | N/A | 1100–1300 | N/A | [97] | ||||
Metoprolol | HD | 2.9 (Met = 5) | 8 | 2.3–3 | 3–5 | 101 | 8 | 800–1200 | ||||
HP | 2.2 | 1 | 96.1 | 1 | ||||||||
Nadolol | HD | 3.5 | 6 | 3.0–8.5 | 10–15 | 30–45 | 82 | 15 | 46.4–102 | 120–250 | 30 | |
Oxprenolol | HD | Met = 5.6 | 3 | 1–2 | N/A | 600–750 | 550 | [84] | ||||
Practolol | HD | 14 (Met = 5) | 14 | 8–30 | 10–13 | 60–80 | > 100* | 6 | 135 | 20 | ||
Propranolol | HP | 5.6 | 3 | 4.9–8.9 | 3–5 | 189 | 2 | 188–191 | 800–1200 | |||
HD | 3.4 | 23 | 1.5–8 | 9.4 | 11 | 3.8–26.5 | ||||||
TPE | 1.2 | 1 | N/A | |||||||||
Sotalol | HD | 7 | 9 | 3.5–9.5 | 5–9 | 35–60 | 80 | 3 | 67–80 | 120–160 | 20–25 | |
HP-HD | 2.8 | 1 | N/A | |||||||||
CKRT | 18 | 1 | 53.1 | 1 | ||||||||
Talinolol | HD | N/A | 10–12 | 20–25 | 28 | 7 | 320–380 | |||||
HP | 3.3 | 2 | 2.7–3.8 | 109 | 2 | 96–121 | ||||||
Timolol | HD | 3.8 | 2 | 2.3–5.2 | 3–5 | N/A | 450–580 | N/A | [72] |
Drug | PK/TK grading | Number of patients | Final grading and level of evidence | |||||
---|---|---|---|---|---|---|---|---|
HD | PD | CKRT | HP | TPE | HP-HD | |||
Acebutolol | Dialyzable | 1, MET = 2 | HD: Moderately dialyzable, D* HD (MET): Moderately dialyzable, C | |||||
Moderately dialyzable | 1, MET = 1 | |||||||
Slightly dialyzable | 1, MET = 1 | |||||||
Not dialyzable | ||||||||
Atenolol | Dialyzable | 24 | HD: Dialyzable, A CKRT: Slightly dialyzable, C HD-HP: Moderately dialyzable, D PD: Not dialyzable, B | |||||
Moderately dialyzable | 1 | 1 | 1 | |||||
Slightly dialyzable | 2 | |||||||
Not dialyzable | 7 | |||||||
Betaxolol | Dialyzable | HD: Not dialyzable, B PD: Not dialyzable, C | ||||||
Moderately dialyzable | ||||||||
Slightly dialyzable | ||||||||
Not dialyzable | 12 | 6 | ||||||
Bisoprolol | Dialyzable | 5 | HD: Moderately dialyzable, B | |||||
Moderately dialyzable | 14 | |||||||
Slightly dialyzable | ||||||||
Not dialyzable | ||||||||
Carvedilol | Dialyzable | HD: Not dialyzable, B | ||||||
Moderately dialyzable | ||||||||
Slightly dialyzable | ||||||||
Not dialyzable | 8 | |||||||
Labetalol | Dialyzable | HD: Not dialyzable, B PD: Not dialyzable, C | ||||||
Moderately dialyzable | ||||||||
Slightly dialyzable | ||||||||
Not dialyzable | 17 | 8 | ||||||
Mepindolol | Dialyzable | HD: Not dialyzable, C | ||||||
Moderately dialyzable | ||||||||
Slightly dialyzable | 1 | |||||||
Not dialyzable | 1 | |||||||
Metipranolol | Dialyzable | HD: Moderately dialyzable, C | ||||||
Moderately dialyzable | 4 | |||||||
Slightly dialyzable | ||||||||
Not dialyzable | ||||||||
Metoprolol | Dialyzable | M = 2 | HD: Slightly dialyzable, B HD (MET): dialyzable, C HP: Slightly dialyzable, D (Normal GFR) | |||||
Moderately dialyzable | ||||||||
Slightly dialyzable | 8 | 1 (Normal GFR) | ||||||
Not dialyzable | ||||||||
Nadolol | Dialyzable | 6 | HD: Dialyzable, B | |||||
Moderately dialyzable | ||||||||
Slightly dialyzable | ||||||||
Not dialyzable | ||||||||
Oxprenolol | Dialyzable | MET = 3 | HD (MET): Dialyzable, C | |||||
Moderately dialyzable | ||||||||
Slightly dialyzable | ||||||||
Not dialyzable | ||||||||
Practolol | Dialyzable | 14 | HD: Dialyzable, B | |||||
Moderately dialyzable | ||||||||
Slightly dialyzable | ||||||||
Not dialyzable | ||||||||
Propranolol | Dialyzable | 1, MET = 2 | HD: Not dialyzable, A HD (MET): Dialyzable, C HP: Slightly dialyzable, D (Normal GFR) | |||||
Moderately dialyzable | 2 | 1** | ||||||
Slightly dialyzable | 2 (Normal GFR) | |||||||
Not dialyzable | 13 | |||||||
Sotalol | Dialyzable | 6, 1 (Normal GFR) | HD: Dialyzable, B HD: Dialyzable, D (Normal GFR) CKRT: Slightly dialyzable, D HD-HP: Moderately dialyzable, D (Normal GFR) | |||||
Moderately dialyzable | 1 | 1 (Normal GFR) | ||||||
Slightly dialyzable | 1 | |||||||
Not dialyzable | ||||||||
Talinolol | Dialyzable | HD: Slightly dialyzable, B HP: Slightly dialyzable, C (Normal GFR) | ||||||
Moderately dialyzable | ||||||||
Slightly dialyzable | 8 | 2 (Normal GFR) | ||||||
Not dialyzable | ||||||||
Timolol | Dialyzable | HD: Not dialyzable, D | ||||||
Moderately dialyzable | ||||||||
Slightly dialyzable | 1 | |||||||
Not dialyzable | 1 |
Clinical data
Acebutolol (n = 4) | Atenolol (n = 9) | Carvedilol (n = 1) | Metoprolol (n = 1) | Propranolol (n = 9) | Sotalol (n = 9) | Talinolol (n = 4) | |
---|---|---|---|---|---|---|---|
Patient characteristics | |||||||
Age, years | 20 (17–27) | 45 (28–74) | 21 | 49 | 31 (15–49) | 66 (44–78) | 21 (20–47) |
Men, % | 0 | 56 | 0 | 0 | 44 | 78 | 50 |
ESKD, % | 0 | 11 | 0 | 0 | 0 | 44 | 0 |
Poisoning information | |||||||
Intentional overdose, % | 100 | 89 | 100 | 100 | 100 | 44 | 100 |
Dose if acute ingestion, g | 8.4 (4.8–12) | 4.5 (2.5–10) | 1.8 | 0.5 | 3.1 (0.6–5.0) | 8.0 (7.2–14.4) | 2.5 (1.5–5.0) |
Peak concentration, mg/L | 14 (10–18) | 14 (2.5–70) | 0.6 | 2.8 | 1.5 (0.04–3) | 17 (2.5–65) | 5.5 (5.0–6.1) |
Time from ingestion to admission, hours | 2 (2–2) | 6.5 (2–8) | 0.8 | 2 (1–8) | 2.5 (1–4) | 6 (2–8) | |
Signs/ Symptoms / Labs | |||||||
Coma, % | 100 | 89 | 100 | 100 | 50 | 100 | 75 |
Altered consciousness, % | 100 | 100 | 100 | 100 | 83 | 100 | 75 |
Bradycardia, % | 100 | 100 | 100 | 100 | 100 | 50 | 100 |
Severe dysrhythmia, % | 25 | 0 | 100 | 0 | 33 | 100 | 25 |
Hypotension, % | 100 | 100 | 100 | 100 | 75 | 89 | 100 |
QRS complex duration, msec | 260 | 128 (98–160) | N/A | N/A | 104 | 120 (104–140) | 420 |
Prolonged QRS complex duration, % | 100 | 43 | 0 | 0 | N/A | 25 | 50 |
QT interval duration, msec | N/A | 440 (400–448) | N/A | N/A | N/A | 618 (509–880) | 440 |
Prolonged QT interval, % | N/A | 17 | N/A | N/A | N/A | 100 | 25 |
Acute kidney injury, % | 100 | 87.5 | 100 | 0 | 0 | 38 | 0 |
Serum glucose, mmol/L | 14.7 | 7.7 (2.2–19.2) | 8.3 | N/A | 10.7 | 4.4 (1.4–7.4) | N/A |
Serum bicarbonate, mmol/L | 16 | 19 (10.8–21) | N/A | N/A | 20 (15–25) | 17 | N/A |
Serum lactate, mmol/L | 1.9 | 4.6 (1.8–9.3) | 4.7 | N/A | 7.6 (1.9–13.2) | 1.9 | N/A |
Serum potassium, mmol/L | 3.2 | 4.3 (< 0.8–8.5) | 5.9 | N/A | 4.2 (3.7–4.7) | 5.1 (3.8–7.1) | N/A |
Other treatments | |||||||
Gastric lavage, % | 25 | 44 | 0 | 0 | 67 | 22 | 75 |
Activated charcoal, % | 75 | 56 | 0 | 100 | 50 | 11 | 25 |
Vasopressors/ inotropes, % | 100 | 100 | 100 | 100 | 50 | 75 | 75 |
Mechanical ventilation, % | 100 | 100 | 0 | 100 | 17 | 75 | 75 |
Atropine, % | 100 | 56 | 0 | 100 | 67 | 22 | 25 |
Lipid emulsion, % | 0 | 11 | 0 | 0 | 16 | 0 | 0 |
Pacemaker, % | 100 | 44 | 100 | 100 | 33 | 88 | 50 |
High-dose insulin euglycemic therapy, % | 0 | 67 | 0 | 0 | 33 | 0 | 0 |
Glucagon, % | 75 | 100 | 100 | 100 | 83 | 33 | 25 |
Extracorporeal life support (ECLS), % | 25 | 22 | 100 | 0 | 0 | 0 | 0 |
Extracorporeal treatments | |||||||
Hemodialysis, n | 1 | 3 | 0 | 0 | 0 | 6 | 0 |
TPE, n | 0 | 0 | 1 | 0 | 2 | 0 | 0 |
CKRT, n | 0 | 3 | 0 | 0 | 0 | 1 | 0 |
More than 1 ECTR, n | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
HF-HP, n | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
HD-HP, n | 1 | 1 | 0 | 0 | 3 | 1 | 1 |
HP, n | 1 | 0 | 0 | 1 | 4 | 0 | 3 |
Outcome | |||||||
Death, % | 0 | 11 | 0 | 0 | 11 | 11 | 50 |
Sequelae, % | 25 | 11 | 0 | 0 | N/A | 11 | N/A |
Length of stay, days | 30 (7–49) | 22 (12–32) | 23 | N/A | 6 (5–32) | 20 | N/A |
Length of ICU stay, days | 2 (2–2) | 9.5 (1.5–28) | 8 | 3 | 8.5 (4–13) | 3 (2–6) | N/A |
Length of life-threatening dysrhythmia | N/A | N/A | N/A | N/A | 56 | 16 (12–120) | N/A |
Length of prolonged QT interval, msec | N/A | N/A | N/A | N/A | N/A | 37 (30–120) | N/A |
Length of bradycardia/hypotension, hours | 25 (24–26) | 48 (20–168) | 120 | 18 | 67 (24–70) | 36 | 9 |
Quality assessment | Summary of findings | Importance | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Drug | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | ECTR + standard care | Standard care (controls) | Impact | Quality | |
Mortality | |||||||||||
All β-adrenergic antagonistsa n = 10 | Observational studies | Very seriousb | Not serious | Serious c | Serious d | Publication bias strongly suspected e | 13.5% (5/37) | ICU data 8.2% (9/110) admitted in 1 ICU 2002–9 [23] PCC and hospital data 3.8% (63/1678) 0/858: German PCC 2001–11 single-substance [32] 1/11: children, self-harm [50] 2/73:1 hospital 1993–7 [37] 0/40: 1 hospital 1966–80 [25] 4/280: 2 PCCs 1992–8, [22] | Comparable mortality between the ECTR group and the control group admitted to ICU (risk difference = 53 more deaths per 1000 patients in the ECTR group (with a 95% CI from 68 less to 175 more deaths per 1000) | ⨁◯◯◯ VERY LOW | CRITICAL |
Propranololf n = 5 | Observational studies | Very seriousb | Not serious | Serious c | Serious d | Publication bias strongly suspected e | 11.1% median dose 3.1 g (1/9) | Ranging from 0 to 2.1% 0/41 German PCC 2001–11 single substance median dose 0.4–0.5 g [32] 7/339 UK PCC 2017–18, median dose 0.6 g [321] 0/50: 1 hospital 1993–7 mean dose 1.3 g [37] 0/18 1979–1985 mean dose 1.6 g [36] | Groups not comparable | ⨁◯◯◯ VERY LOW | CRITICAL |
Sotalolg n = 3 | Observational studies | Very seriousb | Not serious | Serious c | Serious d | Publication bias strongly suspected e | 11.1% median 8.0 g (1/9) | Overall = 0% 0/31: German PCC 2001–11 single substance [32] 0/6: Case in Finland 1977–1980, mean dose 5.7 g [12] | Groups not comparable | ⨁◯◯◯ VERY LOW | CRITICAL |
Atenololh n = 3 | Observational studies | Very seriousb | Not serious | Serious c | Serious d | Publication bias strongly suspected e | 11.1% median 4.5 g (1/9) | Overall = 0% 0/48: German PCC 2001–11, single substance, median dose 0.5–0.8 g [32] 0/10: 1 hospital 1993–7 mean dose 2.0 g [37] | Groups not comparable | ⨁◯◯◯ VERY LOW | CRITICAL |
Duration of QT interval prolongation | |||||||||||
Sotaloli n = 4 | Observational studies | Very seriousb | Not serious | Serious c | Serious d | Publication bias strongly suspected e | Median = 37 h [33.5, 78.5] 3 pts, median 8 g | Median = 75 h [57, 87.5] 6 pts median dose 6.2 g 1977–80 [12] | No formal comparison possible due to the small sample size of the ECTR group | ⨁◯◯◯ VERY LOW | IMPORTANT |
Serious complications of catheter insertion j | |||||||||||
n = 5 k | Observational studies | Not serious | Not serious l | Not serious m | Not serious n | Strong association o | Rate of serious complications of catheter insertion varies from 0.1% to 2.1% | ≈ 0 | Absolute effect is estimated to be varying from 1 to 21 more serious complications per 1000 patients in the ECTR group | ⨁⨁⨁◯ MODERATE | CRITICAL |
Serious complications of ECTR p | |||||||||||
n = 4q | Observational studies | Not serious | Not serious | Not serious | Not serious | Strong association r | Rate of serious complications of ECTR varies according to the type of ECTR performed from 0.005% (IHD and CKRT), to 0.6% (TPE) and up to 1.9% (HP) | ≈ 0 | Absolute effect is estimated to be varying from > 0 to 19 more serious complications per 1000 patients in the ECTR group depending of the type of ECTR performed | ⨁⨁⨁◯ MODERATE | CRITICAL |
Discussion
Recommendations
General statements and indications for ECTR
-
In patients severely poisoned with propranolol, we recommend against performing ECTR in addition to standard care rather than standard care alone (strong recommendation, very low quality evidence).
-
In patients severely poisoned with atenolol and kidney impairment*, we suggest performing ECTR in addition to standard care rather than standard care alone when refractory bradycardia and hypotension is present (weak recommendation, very low quality evidence)
-
In patients severely poisoned with atenolol and normal kidney function, we make no recommendation for or against performing ECTR in addition to standard care rather than standard care alone (no recommendation, very low quality evidence)
-
In patients severely poisoned with sotalol and kidney impairment*, we suggest performing ECTR in addition to standard care rather than standard care alone when refractory bradycardia and hypotension and/or recurrent torsade de pointes is present (weak recommendation, very low quality of evidence)
-
In patients severely poisoned with sotalol with normal kidney function, we make no recommendation for or against performing ECTR in addition to standard care rather than standard care alone (no recommendation, very low quality evidence).
-
In patients severely poisoned with sotalol, we suggest against performing ECTR solely based on the QT interval (weak recommendation, very low quality evidence).